AME临床研究评论｜CheckMate 817: 扩大符合免疫检查点抑制剂治疗的晚期非小细胞肺癌患者范围

文章预览

医学评论英文版原文： Baloush Z, Ellis PM. CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer. AME Clin Trials Rev 2024;2:2. 被点评研究： Ready NE, Audigier-Valette C, Goldman JW, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer 2023;11:e006127. CheckMate 817: 扩大符合免疫检查点抑制剂治疗的晚期非小细胞肺癌患者范围 Ziad Baloush 1,2 , Peter M. Ellis 1,2 1 Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada; 2 Department of Oncology, McMaster University, Hamilton, ON, Canada 翻译：张微微；审校：张正 关键词： 非小细胞肺癌（NSCLC）；免疫检查点抑制剂（ICI）；安全性；体能状态差（PS差）；固定剂量 背景 近年来，自免疫检查点抑制剂 ………………………………